首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial
【2h】

Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial

机译:在心力衰竭患者中评估速释卡维地洛-IR与缓释卡维地洛-SR的临床疗效和治疗质量的评估:一项随机对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundCarvedilol is a non-selective, third-generation beta-blocker and is one of the cornerstones for treatment for patients with heart failure and reduced ejection fraction (HFrEF). However, due to its short half-life, immediate-release carvedilol (IR) needs to be prescribed twice a day. Recently, slow-release carvedilol (SR) has been developed. The aim of this study is to evaluate whether carvedilol-SR is non-inferior to standard carvedilol-IR in terms of its clinical efficacy in patients with HFrEF.
机译:背景卡维地洛是一种非选择性的第三代β受体阻滞剂,是治疗心力衰竭和射血分数降低(HFrEF)的患者的基石之一。但是,由于其半衰期短,因此需要每天两次处方速释卡维地洛(IR)。最近,已经开发了缓释卡维地洛(SR)。这项研究的目的是评估卡维地洛-SR对HFrEF患者的临床疗效是否不逊于标准卡维地洛-IR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号